POPULARITY
3 episodes with revolutionise
6 episodes with revolutionise
2 episodes with revolutionise
2 episodes with revolutionise
2 episodes with revolutionise
2 episodes with revolutionise
3 episodes with revolutionise
2 episodes with revolutionise
2 episodes with revolutionise
00:00 - Are young people bad with money?10:28 - How would we revolutionise the education system?24:57 - What's your most contrarian view?Today's Sponsors:Mighty: www.mightypartners.com.au/contrarians See omnystudio.com/listener for privacy information.
Rory McGowan is joined by Dr Juho Jalkanen from Faron Pharmaceuticals. In this episode they discuss a new blood cancer trial has shown highly promising results, particularly for patients who have relapsed or live with hard-to-treat forms of the disease. https://faron.com/
Send us a textIn this episode, we speak with Dr Peter Brown and Rowan Beale from 42 Technology, a FuturePrint partner that may have cracked one of digital print's most stubborn challenges: how to efficiently dry aqueous inks—without compromising substrates or sustainability goals.Their RF dielectric drying technology delivers up to 75% energy efficiency, compared to just 5–15% with traditional drying methods such as hot air and near-infrared. Even more compelling, it enables high-quality aqueous ink printing on previously unsuitable materials like plastic films—opening new commercial possibilities for packaging and beyond.
Have you ever wondered what it would take to feed 10 billion people without destroying the planet? In this episode of the Food Matters Live podcast, recorded at our event in Manchester in May 2025, we tackle this question head-on with a leading researcher from the Bezos Centre for Sustainable Protein at Imperial College London. Dr Rodrigo Ledesma-Amaro breaks down the uncomfortable truths about our current food system: agriculture accounts for 33% of global greenhouse gas emissions, we are wasting 30% of everything we produce, and yet demand is skyrocketing as the world population heads toward 10 billion by 2050. He explores three game-changing approaches to alternative proteins that could solve this puzzle, and reveals how cutting-edge science is making the impossible possible, including yeast that's been launched to space to tackle the cost of feeding astronauts. But the real story is how these breakthrough technologies could transform food production right here on Earth. Guest: Dr Rodrigo Ledesma-Amaro, Director, the Bezos Centre for Sustainable Protein
In this episode, I'm breaking down 5 game-changing actions that will disrupt your routine, rewire your beliefs, and fast-track your self-concept shift in 2025. Inside, we explore intuitive detours, future self embodiment, and why the things that feel “extra” are often the exact things that make you magnetic.Let this be the year you surprise everyone... including yourself.LINKSFREE DOWNLOAD THE BAD BITCH BLUEPRINT WORKBOOKefiasulter.com/blueprintSAVE YOUR FREE SPOT IN THE AUDACITY MASTERCLASSefiasulter.com/theaudacityOVERCOMING SELF SABOTAGE MASTERCLASSefiasulter.com/own-your-shft/Let's stay connected: efiasulter.com | Instagram| TikTokRemember to review, subscribe, and share!**Enjoyed this episode? Support the podcast here: ko-fi.com/efias
This week we unveil six game-changing technologies that promise to redefine your financial strategy. We deep dive into essential tools that make up a potent tech stack empowering businesses to streamline operations and enhance profitability. From comprehensive accounting systems like Xero to powerful add-ons such as Dext, Apron, and Mayday, learn how these modern solutions can significantly improve efficiency. Find out why being tech-savvy is now a crucial component for accountants and how these innovations can help businesses stay ahead of the curve. This episode is packed with practical insights and expert advice for those ready to embrace technology in their business operations, providing a clear pathway to grow, innovate, and succeed in the ever-evolving financial landscape. ⭐ Rate, Review & Share this episode with fellow business owners, and let's grow together! ⭐ Subscribe to the weekly newsletter to get Expert Advice Straight to Your Inbox: https://www.profitcashgrowth.com/subscribe VALUABLE RESOURCES Website LinkedIn YouTube Facebook ABOUT THE HOST: Claire Hancott through Profit Cash Growth helps 6 & 7 figure business owners to increase their profit, improve their cashflow and grow their business using their numbers. As a finance director & chartered management accountant, Claire has nearly 20 years' experience in finance and running businesses of her own. This gives her a unique insight into the information and support business owners need to grow a financially successful business. Claire passionately believes that every business should be run by the numbers because the numbers in your business are telling you a story about what is and isn't working and where your opportunities lie. Claire's mission is to provide insightful management accounts, reports and advice to business owners and support them to make smarter decisions. *The content of this podcast is for entertainment purposes only and does not constitute professional advice.
The modern Indian woman is a force to be reckoned with. In the India our parents grew up in, gender roles were clear. The man worked outside the house and brought in the dough. The woman managed the home – cooking, cleaning, and raising the children. But, today's women do it all – working outside, and inside the house. Thankfully, there's technologies that have made domestic work easier. There's mops with long handles, so we don't have to get on our knees. There's vacuum cleaners and washing machines, which significantly reduce how much effort cleaning and washing clothes takes. And then, there's dishwashers, which make doing the dishes significantly less annoying. For now, dishwashers are not a staple in most Indian kitchens. But that was also true for washing machines at one point–can dishwashers be the next major upgrade to our lives? Let's find out, in the latest episode of The Signal Daily! The Core and The Signal Daily is ad supported and FREE for all readers and listeners. Write in to shiva@thecore.in for sponsorships and brand studio requirementsFor more of our coverage check out thecore.inSubscribe to our NewsletterFollow us on:Twitter | Instagram | Facebook | Linkedin |
Are You Searching For Deeper Meaning In Your Life And Your Love Life? In this episode of The Love Machine podcast, host James Preece is joined by the remarkable Michelle Bell, founder and CEO of Cosmic Fusion. Michelle has developed a revolutionary astrology platform that uniquely combines Western and Chinese astrology. With over a hundred thousand captivated users, this app offers hyper-personalized guidance that can transform how we date, connect, and navigate our lives and relationships. Together, James and Michelle delve into how astrology can be more than just predictions, offering insights into personality, compatibility, and life choices. They explore how Michelle's app, Cosmic Fusion, can help decode personal traits, improve communication, and even guide people in their careers. Listen in as they discuss the app's features, the importance of open-mindedness, and how it serves as a powerful tool to initiate conversations and self-discovery. Whether you're a believer in astrology or a sceptic, this episode promises to offer insights that could potentially change your perspectives on love and relationships. Get ready to unlock cosmic secrets and start a journey toward a better understanding of yourself and your connections with others. About Cosmic Fusion WEBSITE INSTAGRAM
In this episode of Tried and Tested, Sarah Marie is joined by special guest Liv James, Mamamia's style guru and social media queen. The duo put two viral beauty hacks to the test - both promising to simplify your routine with just one product. Liv tries the famous "one lip liner for everything" hack from Emily Wood, sister of White Lotus' Amy Lou Wood. This hack went viral with 28 million views and even caught Kim Kardashian's attention. Meanwhile, Sarah Marie tries out the pre-wash coconut oil hair treatment that's blowing up on TikTok... and blowing her mind! LINKS TO EVERYTHING MENTIONED: Rimmel London Lasting Finish Lip Liner $13 Victoria Beckham Contour Stylus $63 Coconut oil $4.30 FOR MORE WHERE THIS CAME FROM: Watch this and more You Beauty on Youtube Get in the know on our socials: You Beauty Instagram Subscribe to Mamamia Sign up for our free You Beauty weekly newsletter for our product recommendations, exclusive beauty news, reviews, articles, deals and much more! GET IN TOUCH: Got a beauty question you want answered? Email us at youbeauty@mamamia.com.au or send us a voice message, and one of our Podcast Producers will come back to you ASAP. Join our You Beauty Facebook Group here. You Beauty is a podcast by Mamamia. Listen to more Mamamia podcasts here. CREDITS: Hosts: Sarah Marie Fahd & Liv James Producer: Mollie Harwood Audio Producer: Tegan Sadler Video Producer: Marlena Cacciotti Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present, and extend that respect to all Aboriginal and Torres Strait Islander cultures.Become a Mamamia subscriber: https://www.mamamia.com.au/subscribeSee omnystudio.com/listener for privacy information.
Do you find yourself setting the same goals year after year, only to leave them unaccomplished?If so, it might be time to try a new strategy for planning your goals. In this quick win I’m joined by ABC broadcaster and Host of ‘This Working Life’, Lisa Leong to talk about why a pre mortem could be the strategy you need to set achievable goals for the year. Lisa shares: What a ‘pre-mortem’ is and how it can help you set achievable goals for the next year How to make sure a ‘pre-mortem’ works if you are doing it for a team Why a ‘pre-victorum’ is essential to do as well if you are setting personal goals Listen to the full interview with Lisa here. Connect with Lisa via Instagram, or check out ‘This Working Life.” My latest book The Health Habit is out now. You can order a copy here: https://www.amantha.com/the-health-habit/ Connect with me on the socials: Linkedin (https://www.linkedin.com/in/amanthaimber) Instagram (https://www.instagram.com/amanthai) If you are looking for more tips to improve the way you work and live, I write a weekly newsletter where I share practical and simple to apply tips to improve your life. You can sign up for that at https://amantha-imber.ck.page/subscribe Visit https://www.amantha.com/podcast for full show notes from all episodes. Get in touch at amantha@inventium.com.au Credits: Host: Amantha Imber Sound Engineer: The Podcast ButlerSee omnystudio.com/listener for privacy information.
PACE, Fexco's leading aviation sustainability data and analytics platform, has expanded its product offering with PACE Airports and is announcing Christchurch Airport as its first customer. PACE has established itself as the market leader for aviation financiers and is trusted by the world's largest banks, like JP Morgan, and the second largest aircraft lessor in the world, SMBC AC, to inform them on their financed aviation emissions. Christchurch Airport is a global leader in sustainable airport management and a pioneer in the Airport Carbon Accreditation (ACA) program. It is the first airport in the world to reach level 4 in 2020 and to achieve level 5 accreditation in 2023. It is among only 18 other airports worldwide to achieve this rating. The airport chose PACE Airports so they can track, analyse and action live data rather than on an annual basis. Leveraging multiple new data points allows the sustainability team to have more accurate data-led conversations with airline operators and external stakeholders. Airports globally are challenged to understand and track their aviation-related emissions. One of the leading causes of this is a considerable lack of consistency within the industry in defining a standardised methodology that can be independently verified. Calculating carbon emissions is usually done on an annual basis at the end of the year, so the lack of real-time data inhibits airports from making actionable decisions to lower their carbon footprint. PACE Airports offers real-time aviation emissions calculations at the click of a button, allowing sustainability teams to focus on the actions rather than the calculations. In addition, banks can use PACE Airports to evaluate emissions in airport financing deals. Both banks and airports can rely on a single source of truth for emissions metrics to measure performance in sustainability-linked finance deals. PACE Airports tracks all commercial flight activity globally and calculates specific emissions based on over 10 billion data points, right down to the engine on the wing. It is highly configurable to allow airports to track specific runway taxi times and distances, enabling them to drill down into the minute details for highly accurate output data. Claire Waghorn, Sustainability Transition Leader at Christchurch Airport, said: "Christchurch Airport has always leaned into sustainability and innovation. We first started tracking our emissions in 2006, and we have continually challenged what more we can do in decarbonisation through innovation and adaptability. Our strategy has always been data-driven, and PACE unlocks a new level of insight and intelligence that is really exciting for us as we continue our sustainability journey. "At Christchurch Airport, our key focus on this sustainability journey has always been optimising our entire operations to reduce emissions; the insights from the PACE Airports platform now give us data to consider our aviation-related emissions across the entire airport operations." Bertie Murphy, CSO of Fexco Group, added: "Our vision at PACE is to be the independent aviation emissions source across the aviation value chain, trusted and relied upon by all stakeholders. Expanding into Airports is a natural next step in the evolution of our product. We are thrilled to welcome Christchurch Airport, a global leader in sustainability, as a customer. We are enthused to see the impact the data and insights from PACE are having at Christchurch Airport, supporting the team in delivering on their emissions reduction targets." PACE delivers up-to-date emissions data, covering over 99% of commercial flights, recording over 370,000 individual routes and over 10 billion flight data points, which are updated every 24 hours. PACE is trusted by the largest aviation financiers in the world, such as JP Morgan Chase, and SMBC AC, the second largest aircraft lessor in the world. See more stories here. More about Irish Tech News Irish Tech News are Ireland's...
There is a serious Masters come-down in the GIRML office, but do not worry because that will not stop the lads bringing you their bi-weekly #TepidTakes. This week they cover: the fear of golf after a GREAT round, can instagram golf girls change your game, GolfBidder email corner returns again and Green has a rant about football strips on golf courses. Checkout Golfbidder HERE - Email us and win £50 to spend at Golfbidder! - thetoms@golfisruiningmylife.co.uk Tik Tok Youtube - New episodes every Monday & Thursday!! Learn more about your ad choices. Visit podcastchoices.com/adchoices
In a major move to modernise public sector operations, the Government has officially launched InfoCloud Suite a state-of-the-art, cloud-based financial management system. The new platform promises to streamline transactions, boost efficiency, and strengthen cybersecurity, marking a significant milestone in the country's digital transformation journey.
Low-Cost RDP Housing: CSIR's Brick Innovation May Revolutionise Housing in South Africa by Radio Islam
It's UnPsytled Banter Podcast as Psy White goes solo to tackle your questions on Resident Evil, Pokémon, Nintendo, Silksong, Severance, working at WhatCulture and more. Hosted on Acast. See acast.com/privacy for more information.
Send us a textIn this special episode of Marketing in the Madness, recorded at the buzzing Shoptalk conference in Las Vegas, Katie sits down with Dominik Angerer, Co-Founder and CEO of Storyblok, one of the most exciting CMS players revolutionising digital experiences through composable architecture and AI innovation.With 260,000+ users and a fast-growing global team, Dominik shares the inside story of Storyblok's rapid ascent from its first 1,000 users in 3 months to becoming a global CMS powering leading retail and enterprise brands. If you're a Founder or Marketing Leader curious about scalable content strategies, modern tech stacks, or how to unshackle your brand from legacy systems, this conversation is an absolute MUST!1. Kill the Content GraveyardLegacy CMS platforms were built to publish and forget. Storyblok flips that on its head with a full content lifecycle approach—starting with ideation (Ideas Room), mapping out user journeys (Concept Room), and ending with automated updates. 2. Composable Is the FutureWhy buy into a monolith when you can plug in best-in-class tools across CMS, DAM, commerce, and more? Dominik explains why the smartest brands are building their stack modular, flexible, and made to scale.4. Think replatforming takes months? Think again. One Storyblok client went live in 17 markets in just 60 days. Another launched a full proof-of-concept in a week. With the right partners and tools, you can move fast and smart!Ready to see how the smartest tech brands are scaling faster, working smarter, and leaving legacy tech behind?Watch the full episode now to hear how Storyblok is rewriting the rules of content management and why composable, AI-powered platforms are the future for marketing leaders who want more impact and less drag!Storyblokhttps://www.storyblok.com/Dominik Angererhttps://www.linkedin.com/in/dominikangerer/Katie Street:https://www.linkedin.com/in/katiestreet/https://www.instagram.com/streetmate/Marketing in The Madnesshttps://marketinginthemadness.buzzsprout.com/https://www.linkedin.com/company/marketing-in-the-madness-podcast/https://www.instagram.com/marketinginthemadness/ Follow Street Agency:https://street.agency/https://www.instagram.com/street.agency/https://www.linkedin.com/company/streetagency/
Udemy is the San Francisco-based company changing how we learn new skills. Udemy offers online courses ranging from how to use Microsoft Excel to how to build high-performing teams. Now it plans to use new AI technology to provide personalised coaching and training. In the latest episode of the Business Leader Podcast, Graham Ruddick meets Udemy chief executive Hugo Sarrazin to talk about its plans and the challenges of scaling-up a new tech giant Hosted on Acast. See acast.com/privacy for more information.
Tesla are planning to build a restaurant in Los Angeles and let's you charge your Tesla and then go grab some food or go watch a movie all in the one spot.See omnystudio.com/listener for privacy information.
CapeTalk’s Sara-Jayne Makwala King (in for Clarence Ford) is joined by Ross Fitzcharles, founder and CEO of Preferental.See omnystudio.com/listener for privacy information.
Send us a textEver wondered what connects the discipline of a three-time Oxford-Cambridge boat race rower with the intricacies of sustainable architecture and the practicalities of installing heat pumps? This week, Nathan Gambling sits down with Henry Pelly, an extraordinary individual who seamlessly blends these worlds. Our guest is a Principal Sustainability Consultant at the renowned Max Fordham, a qualified architect holding Masters degrees in Environmental Design and Environmental Psychology – a powerful combination for understanding how buildings impact both our planet and our well-being. We explore his fascinating career journey, which has recently taken an exciting turn with the launch of his own MCS installation company, focused on bringing efficient and eco-friendly air-to-water and air-to-air heat pump systems to domestic properties. Discover Henry's incredible past representing Great Britain in rowing, the demands of building a wedding venue, and the heartwarming chaos of family life with three young daughters. Join us for a captivating conversation that proves passion and expertise can truly span diverse and impactful fields.This season is sponsored by Primary Pro, a professional pipe insulation systemSupport the showLearn more about heat pump heating by followingNathan on Linkedin, Twitter and BlueSky
Fitness trackers at the ready! Join James Gallagher at Cardiff Science Festival as he runs through the ways wearable tech is making an impact on health and how it might shape the future of medicines and care. With him are Dr Sanne Lugthart, Haematology consultant at the University Hospital of Bristol and Weston NHS Foundation Trust. She's pioneering using wearables and an app to track pain in people who suffer from sickle cell disease. Also on the panel is Professor Kathryn Peall who is Personal Chair, Division of Psychological Medicine and Clinical Neurosciences at Cardiff University. Kathryn tells James all about working with data from the UK Biobank to test if wearables could predict Parkinson's disease. She's also developing 80s-style headbands that could help take hospital grade sleep monitoring to the comfort of the bedroom. And, running experiments with the audience and on his skydiving assistant Danni, James is also joined by Damian Bailey, Professor of Physiology and Biochemistry from the University of South Wales.Presenter: James Gallagher Producers: Tom Bonnett and Hannah Robins Production Co-ordinator: Ishmael Soriano Editor: Colin Paterson
In this episode I talk with Susan Hensley who has literally written the book on how we can revolutionise our journalling by introducing play, colour and art into our practice. Introducing this element of freedom, expands our ability to be creative in all aspects of our life. It allows us to relate to colour, form and image so that we can start to see patterns within our life, interpret what appears on the page and deepen our self-knowledge. You can find Susan at https://susan-hensley.com/
Guests: Emma Bridger Despite 20 plus years of focusing on employee engagement, we have seen little improvement – according to some studies employees are actually less engaged today than they have ever been! Why? Because we need to focus on intentionally designing experiences that deliver engagement, rather than focusing on engagement as an end in its own right. This starts by asking and understanding what a great EX looks and feels like. In this session, Emma Bridger and Lee Smith, share the findings of People Lab research spanning more than 15 years which answers that seemingly simple question, along with a simple, practical, but powerful tool that will enable you to discover what will make the difference in your own organisation Bought to life with real world stories about what makes a great experience at work and informed by robust research and the cutting-edge EX thinking, you'll leave this session with a clear understanding of the components of great EX and a powerful approach you can deploy to kick-start your organisation's journey towards it. The world of work has changed – we're now in the era of EX and we invite you to come along to this session as we share the tools and insights to transform workplaces into vibrant hubs of excellence. Join us as we discuss why engagement levels are still struggling—or even declining Host: Jo Dodds
What does it really take to become a great fundraising organization? In this powerful episode of the Rainmaker Fundraising Podcast, Andrew Olson is joined by Alan Clayton, author of Great Fundraising Organizations and founder of Revolutionise. Together, they explore what separates thriving nonprofits from those that struggle, why fundraising success starts with leadership, and how to run two distinct operations—service delivery and fundraising—under one mission. Alan shares insights from global research, practical leadership strategies, and a call to embrace emotional storytelling, strategic investment, and a purpose-driven culture Chapters (00:00:00) - Alan Clayton on the Rainmaker(00:00:52) - Revolutionizing What It Is to Raise Money for Nonprofits(00:01:29) - Great fundraising organizations: The journey from good to great(00:03:08) - Getting organizations to commit to a five year plan(00:04:44) - What Makes Nonprofit Organizations Successful?(00:06:50) - The need for emotionally relevant engagement(00:09:29) - The role of the leader in fundraising(00:13:24) - How to Get Your Salesforce CRM to Work(00:13:59) - Philanthropy: The Leadership Problem(00:16:58) - The Conflict and Tension of the Fundraising(00:21:12) - The 3 Step Process of Brand Management(00:24:31) - In the Elevator With Andrew Carnegie(00:25:17) - What Makes a Charitable Leader So Driven?(00:28:58) - Laughably Leadership: A challenge to the(00:30:53) - Andrew Olson on the Biggest Mistakes Nonprofits Make(00:31:24) - A Few Favors for the Rainmaker
In episode 181 of Inside The Mix, I'm joined by Ableton Live expert and music production mentor Dan Giffin to discuss the key elements that take a producer from hobbyist to professional. We dive into the emotional side of mixing, the power of mentorship, and how evolving technology—including AI—is shaping the future of music creation. Whether you're perfecting your productions or preparing for a live music performance, this episode is packed with valuable insights to elevate your workflow.What You'll Learn:How Ableton Live can be used for live performance and stress-free setupsThe impact of music production mentorship on career growthBreaking down the future of AI in DAWs—is there a DAW with AI?How to prepare for a live music performance without the overwhelmThe importance of emotional connection in mixing over technical perfectionLessons learned from Dan's journey, including humorous real-world experiencesTune in to learn how to refine your craft, embrace new technology, and make music that truly connects with listeners!Wanna follow Dan? Click hereGot a question? I'd love to hear from you! Click here to submit a question, share your social media handles or website, and get featured in a future episode.Plus, one lucky question will win a Starbucks voucher each month! Face Your EarsExplore home recording and music creation with Rich and Justin on 'Face Your Ears'!Listen on: Apple Podcasts SpotifySupport the showWanna listen to my new single 'Separation'? Click here Follow Marc Matthews' Socials:Instagram | YouTube | Synth Music Mastering
A new blood test is being trialed in the UK to detect the early signs of dementia. It is hoped it could identify patients sooner, so they can potentially benefit from drugs that slow the progression of the disease. With more than 400,000 Australians identified by the Government as living with dementia - and a forecast that those numbers could go up to 900,000 by 2050 - that could be a significant breakthrough.
Ever wondered how playfulness and authentic communication could revolutionise workplace culture and accelerate outstanding leadership? In this episode I joined Chris Marshall, Behavioural Scientist and Founder of The Playfulness Institute, as a guest on his 'The Being Playful Podcast'. We talked about how creating the right environment enables both people and businesses to flourish. I shared my perspective on workplace dynamics, revealing how understanding and responding to human needs creates environments where creativity, innovation, and authentic connection can thrive. I explain how focusing on the human side of business leads to better performance and engagement.The conversation explores the deep connection between environment, emotional awareness, and performance, with key insights including:The distinction between controlling performance and creating conditions for excellenceHow acknowledging emotions can transform team dynamicsThe importance of leaders modelling authentic behaviourWhy collective intelligence trumps individual brillianceThe power of understanding and working with our natural stress responsesWe deep dive into: How creating psychologically safe environments enables peak performanceWhy pausing and self-awareness are crucial for effective leadershipThe importance of normalising emotional responses in professional settingsHow playfulness naturally emerges when stress levels decreaseThe role of curiosity in fostering innovation and connectionThe discussion takes fascinating turns into how both playfulness and emotional awareness can help manage uncertainty, encourage authentic expression, and create environments where innovation flourishes. This leads to more effective leadership and deeper workplace relationships.More about Chris:Chris Marshall is a Behavioural Scientist, Futurist and Psychologist and the founder of The Playfulness Institute, a not-for-profit organisation that helps organisations, teams and leaders cultivate places where humans can thrive through playfulness. Links to contact Chris:LinkedIn:Chris MarshallThe Playfulness InstituteWebsite: www.playfulnessinstitute.orgResources & ReferencesPodcast SurveyLeadership Labs | It's Time for Change (itstimeforchange.co.uk)The Being Playful Podcast (Spotify)The Being Playful Podcast (Apple Podcasts)Playful Insights - Playfulness Institute BlogThree Pillar Playfulness Scale...
It's hard to move on social media these days without bumping into a post on gratitude. If you're wondering what all the fuss is about, this week's classic interview with Chester Elton, “the apostle of appreciation”, is for you. According to Chester, gratitude cuts to the heart of who we really are. Gratitude exists at an emotional level and is about WHO is in our lives, WHAT we find meaningful and HOW we live. If we make time for gratitude, we can find a way to live that makes everything less stressful. Chester and Andrew also discuss the ways we can build gratitude into everyday life, adding meaning and lightness to our daily routines. Chester Elton has carried out extensive research into how gratitude can help us lead in the workplace. His books, co-authored with Adrian Gostick, include Leading With Gratitude and All In: How the Best Managers Create a Culture of Belief and Drive Big Results. Subscriber Content This Week If you're a subscriber to The Meaningful Life (via Apple Podcasts, Spotify or Patreon), this week you'll be hearing: Three things Chester Elton knows to be true. AND subscribers also access all of our previous bonus content - a rich trove of insight on love, life and meaning created by Andrew and his interviewees. Follow Up Get Andrew's free guide to difficult conversations with your partner: How to Tell Your Partner Difficult Things Take a look at Andrew's new online relationship course: My Best Relationship Tools Read Chester Elton's Leading with Gratitude Book Sign up for Chester Elton's free LinkedIn newsletter, The Gratitude Journal Read Chester Elton's article on Why We Should be Grateful for Hard Times Read Jay Shetty's book Think Like A Monk: Train Your Mind for Peace and Purpose Every Day Andrew offers regular advice on love, marriage and finding meaning in your life via his social channels. Follow him on Twitter, Facebook and YouTube @andrewgmarshall
In this episode of Conversations with Leaders, host Sam North engages with Brad Garlinghouse, CEO of Ripple, and Yoni Assia, CEO of eToro, to discuss the transformative potential of cryptocurrency and blockchain technology. They delve into Ripple's mission, the significance of XRP, the impact of regulatory changes, and the future of digital assets. The conversation highlights the importance of stablecoins, the evolving market sentiment, and the challenges of leading in a dynamic industry. Both leaders emphasize the need for long-term vision and the role of institutional adoption in shaping the future of finance.
On 2024's last episode of the Sifted Podcast, Amy is joined by an entrepreneur on a very big mission. Munich-based startup Proxima Fusion is developing a nuclear fusion reactor — a technology which many hope could help solve the climate crisis by producing clean, cheap and abundant energy that could replace a lot of fossil fuel power.But the technical challenges are considerable.Nuclear fusion reactors need to remain stable at incredibly high temperatures, while confining volatile plasma with powerful and sensitive magnets. Proxima Fusion is targeting raising a billion euros to build its technology, with support from European governments and international investors.The company's founder Francesco Sciortino sat down to discuss how his team plans to change the world with its technology, the milestones it needs to hit, by when, and to reflect on the challenges of scaling up ambitious hardware-based deeptech companies from Europe.
Shaun Dendere from Trive SA unpacks the market's reaction to Nampak's update and Anglo American's sale of 6.6% of Amplats – does Amplats still hold an investment case? Absa CIB's Premeshin Naidoo discusses how new energy vehicles could revolutionise SA's auto industry. Conway Williams from Prescient highlights key insights from their 2024 Responsible Investing Report and its importance for investors.
Researchers at the International Energy Research Centre (IERC), based at Tyndall National Institute, are leading research into the use of artificial intelligence (AI) to develop a deeper understanding of the complex factors impacting energy poverty. The project, entitled the Irish Energy Poverty Observatory (IREPO), aims to provide a unique platform that will enable research, development, and policymaking in this area. Energy poverty, where households cannot afford or access sufficient energy services, is influenced by various social, economic, and environmental factors. Existing approaches to understanding energy poverty are limited in their ability to capture all dimensions of the issue, relying heavily on income and expenditure metrics. IREPO aims to overcome these limitations with an innovative, data-driven approach. IREPO, led by Dr Fábio Silva and Dr Pádraig Lyons, is a collaboration between IERC, Professor Aoife Foley from the University of Manchester UK, Professor Patricia Kearney from UCC's School of Public Health and Non-Governmental Organisations who advocate for those experiencing energy poverty, The Wheel and South-East Energy Agency (SEEA). The development of the observatory will leverage from international best practice, and the approach can be used in other jurisdictions to provide similar insights. The project will integrate and synthesise data from an array of sources, including surveys, historical databases, and census data. AI and machine learning algorithms will underpin the development of tools to analyse the diverse dataset and scenarios that a comprehensive view of energy poverty would demand and help identify key factors and trends. The approach will assist policymakers and stakeholders in forming effective strategies and policies to alleviate energy poverty in the context of uncertain geopolitical situations and the urgent need to decarbonise societies throughout the world. Dr Fábio Silva, Senior Research Engineer at the IERC, said: "The development of the Irish Energy Poverty Observatory should provide a unique platform to improve policy actions and support research in this area." Dr Aoife Foley, University of Manchester, said: "Professor Patricia Kearney and I are very excited to work on this novel and world-leading interdisciplinary SEAI-funded project, with Dr Fabio Silva and Dr Padraig Lyons from the IERC, which will develop innovative approaches to analyse, and address the health, well-being, and economic impacts of climate change and Net Zero roadmaps on society to ensure effective and targeted solutions to guide, direct and inform decision-making for all public, private and citizen stakeholders." The project is funded by the Sustainable Energy Authority of Ireland (SEAI).
In this episode, we explore findings from a groundbreaking study recently published in Nature which revealed potential targets for bowel cancer prevention and treatment. The study provides the most detailed understanding yet of bowel cancer's genetic makeup. The research, which used data from the 100,000 Genomes Project identified over 250 genes that play a crucial role in the condition, driver genes and potential drug targets. Our guests discuss the potential impact of these findings on patient outcomes, screening for bowel cancer, and future prevention strategies. Helen White, Participant Panel Vice-Chair for Cancer at Genomics England is joined by Professor Ian Tomlinson, Professor of Cancer Genetics at the University of Oxford, Claire Coughlan, Clinical Lead for Bowel Cancer UK and consultant nurse in colorectal cancer, and Dr David Church, a clinical scientist fellow and a medical doctor specialising in oncology at Oxford University. "The people that were kind enough to donate samples to the 100,000 Genomes Project, they did so knowing that they almost certainly wouldn't benefit personally from their donation from their gift and that any benefits would be some way down the line and hopefully benefit others which is what we're seeking to realise now. But, you know, it's not a given when we treat people in the clinic so we're very, very grateful to those individuals." You can read more about the study in our colorectal cancer blog and our study findings news story. You can download the transcript or read it below. Helen: Welcome to Behind the Genes. Ian: One of the great hopes is that some of these new genes that we've found could be useful in preventing cancer and it doesn't necessarily matter that they're rare, even if they're only 1% of cancers, by using those and changing those in the normal individual before they have had cancer then we may be able to reduce that risk. So, there are lots of potential new targets for prevention that are coming through. My name is Helen White and I'm the Participant Panel Vice-Chair for Cancer at Genomics England. Today I'm delighted to be joined by Professor Ian Tomlinson, Professor of Cancer Genetics at the University of Oxford, Claire Coughlan, Clinical Lead for Bowel Cancer UK and consultant nurse in colorectal cancer, and Dr David Church, a clinical scientist fellow and a medical doctor specialising in oncology at Oxford University. Today we will be discussing a pioneering colorectal cancer study which using data from the 100,000 Genomes Project has uncovered new insights that could transform diagnosis and treatment for patients with bowel cancer. If you enjoyed today's episode we would love your support, please like, share and rate us on wherever you listen to your podcast. Thank you for joining me today. We're going to be discussing the findings from a landmark study that has been published in nature. This study used data generously donated by people with bowel cancer who took part in the 100,000 Genomes Project giving us the most detailed look yet at the genetic makeup of colorectal cancer better known as bowel cancer. But before we get into that let's start by hearing from my guests. Could each of you please introduce yourselves. Ian: I'm Ian Tomlinson, I work at the University of Oxford and most of my work is research into bowel cancer, it's genetic causes, the genes that are involved in actually causing the cancer to grow which may be different from genetic causes and also the use of that data to help patients whether guiding future treatments or potentially helping to prevent bowel cancer which would obviously be our optimum strategy to have the biggest impact on the disease and its incidents. Claire: So, I'm Claire Coughlan, I'm the clinical lead for Bowel Cancer UK and my remit at the charity is to ensure that everything we do is clinically relevant and that we're providing services that meet the needs of those affected by bowel cancer and the educational needs of those health professionals that work with people affected by bowel cancer. I'm also a nurse consultant in colorectal cancer at Lewisham and Greenwich NHS Trust and I lead an urgent referral service there and also work with patients with late effects of bowel cancer. David: I'm David Church, I'm a medical oncologist and Cancer Research UK advanced clinician scientist at the University of Oxford. I treat bowel cancer clinically and do research on bowel cancer and womb cancer including a lot of research using samples and data from Genomics England data service we're discussing today of course. Helen: Great, thank you. Now let's turn to Claire to learn more about bowel cancer. Claire, can you share with us how common it is, how treatable it is and if there are any trends in terms of which groups of people are affected? Claire: Of course, bowel cancer is a relatively common cancer, there are about 46,000 people each year in the UK diagnosed with bowel cancer so that is quite a large number. The thing that really drives us forward in bowel cancer is that the earlier stage you're diagnosed at the greater chance of survival. So, the figures for that are quite stark, we stage bowel cancer through stage one to 4 with one being the earliest stage and 4 being the most advanced. If you are diagnosed with bowel cancer at stage one you have a 9 in 10 chance of being alive and well 5 years after your diagnosis of bowel cancer. And if you're diagnosed at the other end of the spectrum at stage 4 that drops to a 1 in 10 and should people survive after a diagnosis of stage 4, which more people than before do they will have had a lot of treatment for their bowel cancer so the burden of the treatment will also be with them after that. So, it's really important that we diagnose at the earliest possible stage which is why studies such as the one we're going to talk about today are so important. We have noticed that there has been a slight increase in being diagnosed at a younger age. That said the latest statistic is 2,600 people were diagnosed under the age 50 in the UK last year so it's still a disease of older people, you still have a greater chance of getting bowel cancer as you get older but it's really, really important that we're aware that you can still get bowel cancer as a younger person. Probably one of the most exciting things that has happened for bowel cancer of recent years is our bowel cancer screening programme and the age for that now has been brought down to 50, we're not quite there all over the country, but in the UK that is the aim that everyone will be screened for bowel cancer at the age of 50. So, yes it's a common disease and staging an early detection is vital. Helen: That's lovely Claire, thank you very much for that. David, turning to you could you please explain to us how bowel cancer typically develops? David: Yes, so we know compared with many cancer types quite a lot about how bowel cancer develops because the bowel is accessible to collect samples by a technique called endoscopy which is putting a camera into the bowel from which you can sample tumours or lumps. And so from genetic research done in the last 10 years we know that, or we've known for many years actually, for much longer, that cancer is a genetic disease, it's a disease caused by alterations in genes and particularly genes that control whether the cells in our bowel grow normally and die normally as they should do. And collectively when there are alterations in genes that regulate those processes you can have a cell or collection of cells which are able to grow without restraint and don't die when they should do which are some of the hallmarks of a cancer and they also require the ability to spread elsewhere in the body which is what kills people with cancer including bowel cancer. We know from research done in the last 10 to 15 years that some of the alterations in genes that can cause bowel cancer in combination occur very early in our life, even in the first and second decade of life, but don't cause cancer. The earliest detectable abnormality is typically a polyp which is a tumour, a lump within the bowel which is detectable and if removed is almost certainly cured by removal alone but if it's not detected then as that grows and acquires more alterations in genes then it can become a cancer and cancers develop the ability to invade the bowel wall, to spread to what we call lymph nodes or glands nearby and also to spread further afield, most commonly to the liver or to the lungs. And for most people whom bowel cancer has spread to the liver or to the lungs or elsewhere unfortunately we're not able to cure their disease which as Claire has said is why there is such an importance in detecting cancers and pre-cancers as we call them so that the tumours are not actually cancerous but come before bowel cancer as early as possible. Helen: Thank you David. Moving on to the study, Ian perhaps you can take this, in the study that you carried out my understanding is that the whole genome sequencing was used to investigate the genetic changes that lead to the development and growth of bowel cancer. And for this participants with bowel cancer in the 100,000 Genomes Project donated both a blood sample and a tumour sample while those with rare conditions only provided a blood sample, can you explain why that is? Ian: As you said the study really looked at 2 quite separate arms albeit with a little bit of overlap as we'll see. So, one very important aim was to look at individuals, both children and adults, who had medical problems or other conditions that were unexplained but which had some features that suggested that they weren't necessarily inherited but there may be some variation in their genes that had caused them, and roughly half of the programme was dedicated to that. Within that there was a small number of people who had a strong family history of bowel cancer or who had large numbers of polyps in the bowel and they were analysed in a separate part of the project from what we're mostly discussing. Within the cancer arm there was a collection really throughout England of patients who had most of the common types of cancer and a few with less common cancers. And because when we're looking at genetic and related changes in cancers we need to make sure that those changes have actually occurred in the cancer as it started growing from its earliest stages with a small number of cells in the body that were slightly abnormal and then progressing. We need to look at what genetic variation the patient has in all the cells of their body. We don't want to look at patients and say that looks an interesting change, we may be able to use that if it's present in all of the normal cells in that patient's system. We want to make sure the change is specific to the cancer itself and therefore we have to sequence both a sample probably taken from blood and a sample taken from the actual cancer. And in a way we subtract out the changes in the blood to identify the changes that have actually occurred in the cancer itself. Helen: That's a very helpful explanation. Does this research show that there is a role for whole genome sequencing in clinical care? Ian: I think my own view is it is all a question of cost. I think the advantages it provides it can assess multiple types of genetic change at once. It is relatively consistent across each cancer's genome between cancers, even between centres mean that it is the method of choice. There are undoubtedly developments that will happen in the future, maybe being able to sequence longer stretches of DNA in one go that will help the analysis. And some of the computational methods are likely to develop to identify some of the slightly difficult to identify genetic changes but it ought to be the standard of choice. There are issues and potential difficulties in collecting the high-quality samples that have been needed from pathology laboratory and that will be difficult going forward with current budges and there are lots of challenges but ultimately it in some form has to be the method of choice. What wasn't done is to look at other molecule tests or essays, looking at RNA wasn't really done on a big scale as well as DNA and other changes to DNA apart from the genetic changes were not looked at. So, there are certainly ways it could be improved if you had limitless money but I think the project, 100,000 Genomes has shown the whole genomes are. They have a lot of advantages and ultimately probably will be adopted by the NHS and similar organisations. Helen: David, could you now tell us about the findings of this pioneering study and what impact these findings might have on people with bowel cancer in the future? David: So, this is the largest study to date to analyse the entire genome of bowel cancer by some margin and the fact that we've done whole genome sequencing and in so many people it has really given us an unprecedented ability to identify the genetic alterations that drive bowel cancer. And within bowel cancer we've known for some time it is not a homogeneous entity that bowel cancer is not all created equal, that there are sub-groups of bowel cancer and we have been able to refine those over previous efforts. And I guess if you were to ask what the biggest take home for me from the study is it's just the complexity of the disease. So, as we've mentioned we know that cancer is a genetic disease, that it's driven by genetic alterations, alterations in genes which regulate the growth of cells or the death of cells or the spread of cells. And we've known for many years that there is a modest number of genes which are commonly malfunctioning in bowel cancer and they would be in the tens to dozens really. But with this work we've hugely extended our understanding of the genes that drive bowel cancer and in fact we've discovered nearly 250 genes which are altered in bowel cancer and appear to drive the growth of the cancer. Now we know that not all of those will be validated and by that I mean that there are associations that we find at the moment, not all of which will be biologically relevant but interpreted in the data we know a large number that are previously undiscovered are or we can be fairly confident of that. And one of the take homes from that is that many of these are only altered in a small fraction of bowel cancers. So, rather than being perhaps half of bowel cancers or a third of bowel cancers there are a good number of genes, a very substantial number of genes, which are altered in say 3 to even 1% of bowel cancers. And if we think about how we go about targeting those and perhaps we'll come onto treatment later that poses really challenges for how we work and we would think about treating patients with bowel cancer who have those particular alterations in their cancers. Helen: Thank you David, yes we'll come onto treatment shortly, but I think Claire has a question for you. Claire: Yes, thank you. For me as somebody who works in this every day this is such an exciting and interesting study, particularly in light of what we said earlier about early detection and how critically important that is for improving outcomes in people with bowel cancer. So, in your view do you think this research could help shape future screening programmes or prevention strategies? David: That's a great question, I suppose in terms of screening at the moment the majority of screening is done in the UK at least by testing for blood in the stool which is relatively non-specific so I'm not sure that that would be directly impacted by this research. But one area of early cancer detection that is perhaps more relevant is quite a lot of work including from Oxford actually in recent years looking at blood tests. So, testing blood samples for early detection of cancer whereby you can test for genetic alterations, fragments of DNA that have alterations from the bowel cancer or any cancer that circulates in the blood and that tends to rely on a small number of common alterations. And with this data I could see that we might be able to refine those tests and in so doing improve our early detection of cancer but that would need quite some work before we could actually say look that had real potential I think. And in terms of prevention there are, I think Ian may want to come in on this, one or 2 sub-groups which you might think that you could try to prevent but of course that needs a lot of extra work really. But I think we have some clues of the biology of bowel cancer and particularly some of the sub-groups where you might think well this drug would work better in terms of preventing that sub-group or that sub-group but that will need to be the subject of future study. Helen: Ian, did you want to come in on that at all? Ian: So, at the moment prevention is a fairly new way of helping to reduce the number of people with bowel cancer at the level of the whole population which is what we have in the UK above a certain age group as we heard from Claire earlier. The methods used, again as we heard, are screening for occult blood in the stool and then colonoscopy to identify either hopefully early cancers or polyps and remove those. But when we think about the methods that we use for preventing other diseases then normally where they're successful using a more easily delivered and I have to say less expensive method. So, high blood pressure is treated to reduce the risk of cardiovascular disease and there are other diseases where those what you might call molecularly-based prevented strategies are coming in. We really lack that for bowel cancer in particular, it does happen for some other cancers, but one of the great hopes is that some of these new genes that we've found could be useful in preventing cancer. And it doesn't necessarily matter that they're rare, even if there are only 1% of cancers, by using those and changing those in a normal individual before they have had cancer then we may be able to reduce that risk. So, there are lots of potential new targets for prevention that are coming through and as David said it is going to take a lot of work to work out which of those are deliverable and who will benefit. But we have quite a lot of opportunities in that space and although that may not be us that takes that forward, it may be, but it may not be. We think it is a lot of material for those interested in chemo prevention using drugs of cancer that they can work on and with luck deliver some new ways of preventing cancer that may be simply popping a pill every morning to take your risk right down to as close as zero as we can. Helen: Thank you Ian. David, I think you had something to add here. David: Thanks Helen. One area of prevention that we're really interested in Oxford and many others are is using the genetic alterations that we find in bowel cancers and other cancers as targets for vaccination. Now we know that gene alterations will cause abnormal proteins which while they might drive the cancer, make it grow or not die, can also be recognised by the immune system so the abnormal proteins can be recognised by the immune system as being foreign and as foreign they can be targeted by the immune system so the immune system will try and kill the cells carrying those alterations. And we know for some sub-sets of bowel cancers those alterations can be relatively predictable actually, they occur in quite a sizeable fraction of some sub-groups of bowel cancers. And one area that we're particularly interested in at the moment and actively pursuing is using those targets where you need some additional work to demonstrate when they are particularly recognisable by the immune system. But to use these genetic alterations is potential targets for vaccination with the intention ultimately of preventing bowel cancer in at risk individuals or ideally in the full-term time the whole population. And we've received some funding from Cancer Research UK to pursue this line of research and we have a group working on this in Oxford and as I say many others do elsewhere. Helen: Thank you David, yes I have a vested interest in this because my understanding is this work is aimed primarily at people with a genetic condition called lynch syndrome which predisposes the people who have inherited this gene change alteration to bowel cancer, womb cancer and other cancer. And I had womb cancer, as I think David you know, a few years back and discovered it was due to lynch syndrome and so it's really exciting that you're now looking at vaccinating preventing because yes I take aspirin every day, I have my colonoscopy every 2 years which have some effect on preventing these cancers but it's not 100% guaranteed. And I don't suppose it ever will be but having the vaccination in that armoury would be fantastic I think for future generations, it's very exciting and we look forward to hearing more about it. Thank you Ian and David. I mean we've heard a lot there about preventing bowel cancer but I think moving back now to potential treatments, you know, we've heard from David how this study has shown a number of actionable findings but what are the next steps towards treatment? How can these findings be turned into real actions that will benefit those people diagnosed with bowel cancer in the future? Ian, perhaps you would like to pick up on this to start. Ian: That step is one, you know, in which I'm not personally an expert but a lot of the newer treatments are based on the finding of so called driving mutations which are simply genetic changes that occur as the cancer grows and contribute to that growth and ultimately if it's not treated to the spread and dissemination of a cancer. And the fact that we have reported 250 which need validation but of which a large proportion are likely to be true drivers means that anyone of those can be a potential new target. The criteria to be used for which of those mutations to pursue, which of those driver genes to chase up are quite complicated normally, depend on many things such as the interest of research groups and small and larger drug companies. And the similarity of those genes to other genes that have evolved and the processes that they make to go slightly wrong in the cancer. So, there is also the issue that because these are uncommon, everybody talks a lot about personalised medicine or precision medicine, this would be truly precision or personalised medicine because a genetic change that was driving the cancer in only 1% of patients is obviously not a huge number of patients although bowel cancer is a common cancer so it's not a tiny number either. But it would mean investment at that level to benefit let's say 1 to 2% potentially of all patients with bowel cancer but I think that's a nettle we have to grasp. And I think our results are showing that most of the really common drug changes either have not yet been successfully targeted in treatment or are too difficult to target. So, we're going to have to start looking at these less common genetic drivers and design strategies, inhibitors, you know, again that can be delivered to patients relatively straightforwardly in order to see whether they benefit the patients concerned. But there is this problem of getting enough patients enrolled in clinical trials where a change is only present in a relatively small proportion of all the patients with that cancer type. Helen: Thank you Ian. Presumably if there is a relatively small number of patients the people who are looking at running these trials might be looking at perhaps international trials, would that be one way to go? Ian: So, I think David can speak with more personal knowledge but there are international trial networks and there are collaborations along these lines already under way. I would hope that those could be made use of even more than they are already. There is, you know, a financial consideration for those developing new anticancer treatments which are, you know, high risk work and also the costs of setting up trials and enrolling people is not a trivial thing. So, I think those are hurdles that can be overcome but it would need a concerted effort to do that. Patients will play a major role in that and patient organisations as well as 100,00 Genomes and other similar projects. Helen: Yes, thank you, David I don't know if you want to come in on that. David: Yes, the challenge of testing therapies in small groups is a very real one and there is lots of interest at the moment in exploring alternatives to conventional clinical trials. And as we use more electronic patient records and we have pharmacy records so there is the potential to get those data from routine clinical practice and there is lots of investments and attention on that at the moment so called real world data which is always an interesting term as if patients in clinical trials aren't in the real world which of course they are. But it's perhaps a little more cost effective sometimes in clinical trials, of course it does pose its own challenges in how you disentangle true treatment effect from other factors because there are many factors impacting on how long people with cancer live. But there is a lot of investment and effort going into that at the moment and it will be interesting to see how that develops over the coming years. Helen: Turning to you Claire based on your experience how well do you think people with bowel cancer understand how genomes can help with their care and what support is currently available to them in this area? Claire: I think the answer, as it is so often is, it's dependent on individuals and not just one individual. So, I think some patients are very motivated to know as much about this as possible and to understand and to know what the next steps may be in their own treatment that may be helped by this. Others don't want to have the same knowledge and want to be guided very much by their medical teams but I think oncologists obviously are at the forefront of this and we see at the charity … we have services at the charity that supports patients and we see lots of queries into our ask the nurse service where people have been given variable information about I suppose personalised medicine as Ian alluded to and how their very specific bowel cancer may be treated, so I think it varies from patient to patient. There is support available so we have the ask the nurse service I alluded to. We have a brilliant patient forum actually and everybody in clinical practice will have seen this, patients often become more expert than anybody and they share advice and they're moderated forums that are a very safe place for people to ask questions where there is a moderator to ensure that it is made really clear that circumstances are individual. And the same with the ask the nurse service because you don't have all the clinical information so it is about empowering people, so there is support available. I think the other thing that is really important is equipping specialist nurses with the knowledge that they need to support their patients. This is a really exciting area of evolution for bowel cancer particularly I think in all cancers at the moment but for bowel cancer I think things have changed fairly rapidly in recent years and specialist nurses really need support in knowing that they have up-to-date information to give their patients. So, that's another challenge for us and any specialist nurses that might be listening to this podcast we have online education on genomics for specialist nurses. Just while we're talking about that and you mentioned lynch syndrome earlier, so there has been a lynch syndrome project as I'm sure you're aware where we're trying to get testing for lynch syndrome brought into local hospitals. So, there was some funding via NHS England so that the testing be done at time of diagnosis, so a pre-test and then a final test if that's appropriate, for everybody diagnosed with bowel cancer to see if they have lynch syndrome. And in some trusts that has been done and in others it hasn't yet and the funding hasn't quite followed in the way that we need it to enable that to happen. It's vitally important, we think there are about 175,000 people in the UK with lynch syndrome and we only know about 5% of them. And this is a gene change that is an inherited gene change so we can do what we call cascade testing where we test family members and we can then employ preventative strategies to prevent people from developing bowel cancer. So, it's a really important project, so I think as well as supporting patients with the information around the changes that are happening in this area we also need to ensure that we support the workforce and have investment there to enable the support of all the changes and the genomic landscape. Helen: Absolutely Claire and so much resonates there with what you've said. Having myself had cancer discovered that was due to lynch syndrome, cascade testing offered to my family members so valuable. It turns out I inherited my change from my mum who is 83, has never had cancer, so I think that's a very good example of, you know, it doesn't necessarily mean that you will get cancer but actually on that point that you made about empowering patients I always have a right smile because there is my mum going off to all her other medical appointments because at 83 she sees quite a few people and she is always the one telling them about lynch syndrome and educating them because most of them haven't heard of it, so yes it's really, really important. And that patient forum, you're probably aware of Lynch Syndrome UK, I don't have any involvement in that other than being a member but that is so valuable for people with a particular condition to go somewhere where they can talk to or listen to other people with a similar condition, really, really valuable. Right, well I think circling back really to the 100,000 Genomes Project I think you touched on this earlier David but reflecting on what you and Ian have told us about your study what is it about the 100,000 Genomes Project bowel cancer dataset that made this work possible? David: There are a few things, one of which and not least of which is the sheer size of the effort. So, to have whole genome sequencing for more than 2,000 individuals is previously unprecedented and we'll be seeing more of this now as we scale up our research efforts but at the inception of the project it was very, very ambitious and to be able to deliver that is a huge achievement. And the quality and breadth of the analysis is very strong as well. And ultimately, you know, the former gives thanks to the people that were kind enough to donate samples to the 100,000 Genomes Project, they did so knowing that they almost certainly wouldn't benefit personally from their donation from their gift and that any benefits would be some way down the line and hopefully benefit others which is what we're seeking to realise now. But, you know, it's not a given when we treat people in the clinic so we're very, very grateful to those individuals. And I think also to the scientists who worked incredibly hard over the last 5 years to deliver this work actually. So, having been part of the team and being lucky enough to be part of the team along with Ian we've had hugely motivated individuals that really have dedicated a large fraction of their working lives to delivering this project which I think is a fantastic achievement as well. Helen: Thank you, thank you to all those participants who at a time when their lives probably were turned completely upside down by a cancer diagnosis were offered the chance to join the 100,000 Genomes Project and said yes. As you say most of them will have known that it won't have helped them but by donating their data, you know, it has allowed this work to happen and potentially it could change lots of people's lives in the future, so thank you to them. Ian: Could I also just emphasise and agree with what David has said, I won't go through all the individuals by name, but if anybody wants to read the published report of the work there are several people on there, Alex Cornish is the first author, but many colleagues from an institute of Cancer Research, The University of Manchester, Birmingham, Leeds, other universities in London that all contributed, but also colleagues in the NHS and/or universities who recruited patients, collected samples, processed them etc and of course the people who did the preparation of the samples in genetics laboratories and actually did the sequencing and basic analysis too. So, it is a truly huge effort across particularly all the cancer types which is particularly a complex collection given the fact the tumour is needed and a blood sample. It's quite difficult in a way to find a formal way of thanking them for all of this but without them it wouldn't have happened. Helen: On that note I think we'll wrap up there. A huge thank you to our guests, Professor Ian Tomlinson, Clare Coughlan and Dr David Church for an enlightening discussion on the groundbreaking study published in nature. This research is set to reshape our understanding of colorectal cancer and pave the way for new possibilities in treatment and patient care. If you would like to hear more like this please subscribe to Behind the Genes on your favourite podcast app. Thank you for listening. I have been your host, Helen White. This podcast was edited by Bill Griffin at Ventoux Digital and produced by Naimah Callachand.
Send us a textIn this episode, Darren chats with Michael Adamson, CEO - South Africa at eShandi. The world of lending is undergoing a seismic shift, with innovators like Ishandi redefining what it means to deliver financial services in Africa. Mike shares the journey of this rebranded challenger bank and its mission to address unmet needs in the lending ecosystem across Africa.Highlights:
Send us a textIn this episode, Darren chats with Idan Jaan, Co-Founder & COO at Flexclub. Idan tells us about the many challenges the automotive industry is facing and how FlexClub is transforming vehicle access in South Africa.Highlights:
In this episode of the Digital Disruption Podcast, hosts Pete Gatenby and Chris Williams delve into the role of standardised, shareable data in transforming the home buying and selling process. The discussion focuses on how the adoption of "Horizontal Digital Integration" (HDI) and data standards can significantly streamline transactions, reduce redundancy, and improve customer experiences in the UK property market. Key points include: The Digital Disruption Newsletter: This monthly publication provides insights on digital transformation in home buying and selling. Importance of Data Standards: Implementing reusable data standards can eliminate repetitive tasks, like multiple ID checks, accelerating transaction times and enhancing efficiency. Benefits to Stakeholders: Lenders, brokers, and other actors stand to gain from increased predictability and interoperability. For example, lenders can better predict closing dates, enhancing customer experience and opening new revenue opportunities. Practical Steps for Industry Actors: The episode encourages stakeholders to map their data processes, collaborate within the ecosystem, and invest in technology upgrades to remain competitive. Listeners are also invited to join the live recording event on December 5th 2024, celebrating the 50th episode of the podcast. For more insights, visit our website or connect with us on LinkedIn. To connect with Pete on LinkedIn visit - Pete's LinkedIn profile To connect with Chris on LinkedIn visit - Chris's LinkedIn profile For more insights and assistance in your digital transformation, visit https://www.novus-strategy.com/ and connect with us on LinkedIn at https://www.linkedin.com/company/novus-strategy/ or email us at hello@novus-strategy.com.
Check this out: Guarantee 30 Qualified Project Quotes Over The Next 90 Days! Learn more here: https://tradie.wiki/pod Learn more about the CRM that DOES IT ALL for your trade business! Just click on this link: https://tradiehub.net Join a global community of 6000+ trade professionals https://www.facebook.com/groups/TheSiteShed Connect with me on LinkedIn. For more podcast episodes, you can also visit our website. Thank you for tuning in! If you enjoyed this podcast and this series, please take 5 to leave us a review: Google Facebook Podcast
The scale for which AI will impact the sports industry is up for debate, so StreamTime Sports co-hosts Nick Meacham and Chris Stone decided to have at it. Key points: Does big tech actually impact sports? What are the current practical uses for AI? Is innovation coming for your job? How can AI help leaders make decisions?
Episode 89 - The Courage to Revolutionise the TV Industry - Curtis and Cara Leopardo, started We the Studios a family-owned streaming platform dedicated to providing quality, family-friendly content. Disclaimer: Please note that all information and content on the UK Health Radio Network, all its radio broadcasts and podcasts are provided by the authors, producers, presenters and companies themselves and is only intended as additional information to your general knowledge. As a service to our listeners/readers our programs/content are for general information and entertainment only. The UK Health Radio Network does not recommend, endorse, or object to the views, products or topics expressed or discussed by show hosts or their guests, authors and interviewees. We suggest you always consult with your own professional – personal, medical, financial or legal advisor. So please do not delay or disregard any professional – personal, medical, financial or legal advice received due to something you have heard or read on the UK Health Radio Network.
Episode 140 with Charles Miller, who is Director of Strategic Alliances and Development at Solynta. Charles also serves as a board member of the African Seed Trade Association and on the American Seed Trade Associations International Committee. In addition, Charles is a member of the International Seed Federations Value Chain Expert Group.Solynta uses hybrid potato breeding to grow a more sustainable future. Their mission is to create global solutions for food and nutritional insecurity by offering farmers better, stronger, and more cost-efficient ways to grow crops.What We Discuss With CharlesChallenges faced in promoting hybrid breeding as a solution for more climate-resilient crops in Africa.Given that climate change is impacting global agriculture, how will the seed industry, especially in Africa, evolve in response?How is Solynta ensuring that African farmers have access to potato varieties that can thrive in increasingly unpredictable climates?What are some of the biggest barriers African farmers face in accessing climate-resilient seeds?The major regulatory challenges encountered when scaling seed innovations across different African countries.Did you miss my previous episode where I discuss Leveraging Cloud Technologies to Accelerate AI Innovation and Economic Development in Africa? Make sure to check it out!Like this show? Please leave us a review here -- even one sentence helps!Connect with Terser on LinkedIn at Terser Adamu, and Twitter (X) @TerserAdamuConnect with Charles on LinkedIn at Charles Miller, and Twitter (X) @solyntaDo you want to do business in Africa? Explore the vast business opportunities in African markets and increase your success with ETK Group. Connect with us at www.etkgroup.co.uk or reach out via email at info@etkgroup.co.uk
In this thought-provoking episode, we delve into the extraordinary moment that forever changed my perspective on focus, clarity, and precision—not only in the military but in the chaos of everyday life. I reflect on the struggle between panic and calm, and the lessons learned from a moment of stillness in the heat of the moment, we explore how these principles apply to modern challenges faced by entrepreneurs and business owners. Discover why the urgency to act can often lead us astray, and how finding stillness can enhance our effectiveness and decision-making. This episode reveals six proven techniques to cultivate stillness in both body and mind—essential for achieving optimal performance. Whether you're navigating the pressures of a small business or facing life's daily distractions, learn how to ground yourself and take deliberate aim at your highest values. Tune in to find out how the power of stillness can redefine your approach to success, productivity, and personal growth. Don't miss out on insights that could transform your journey—visit TomFoxley.me for additional resources! Blog Link
In this enlightening episode, Paul Taylor sits down with Dr. Emily Leeming, a dietitian and gut microbiome expert with a PhD from King's College London. They dig deep into the fascinating world of gut health, exploring how what we eat shapes our internal ecosystem and influences our overall well-being. From the surprising impact of early life events on our microbiome to the power of fiber and fermented foods, this conversation covers the latest research and practical tips for nurturing your gut health. Dr. Leeming shares insights from her innovative studies on diet, gut health, and brain inflammation, shedding light on the intricate gut-brain connection. Whether you're curious about the long-term effects of C-sections, wondering why Melbourne has such high allergy rates, or just looking to improve your diet, this episode offers something for everyone interested in the hidden world inside us all. What You'll Learn: Diving into the hidden world of your gut Your microbiome's origin story starts before birth The Impact of birthing method on a newborn's microbiome What influences microbiome development Can you renovate your gut? The truth about microbiome makeovers Gut feelings – How your belly bacteria influence your brain The unsung hero in your digestive drama Not all fiber is created equal A gut-health grocery list Whole foods vs. isolated nutrients - Which is better for gut health? Will your microbes dictate your diet? The future of personalised diets based on individual microbiomes Key Takeaways: Your first dose of microbes comes from birth. Your immune system and your gut microbiome are very much in tandem throughout your life. A more diverse gut microbiome is effectively a healthier gut microbiome. Our gut microbiome is a living ecosystem and we are able to change it throughout our life. Our gut microbiome is involved with our brain, and this can affect our mood, our cognition, and our behaviour as well. Fiber is the closest thing we have to a superfood and is not just important for our gut microbiome but our whole body health. Getting enough fiber rich containing foods and fermented foods that feed our gut bacteria are key important things to have in our diet. The BGBGs – beans, greens, berries, grains, and nuts and seeds are big high fibre hitters and are rich sources of other phytonutrients that are important for our gut and brain health. Connect with Emily Leeming: Website: dremilyleeming.substack.com , https://www.emilyleeming.com/ LinkedIn: linkedin.com/in/dr-emily-leeming-phd-rd-615b5566 Instagram: https://www.instagram.com/dremilyleeming/ Support the Podcast:If you found this episode valuable, please consider subscribing, rating, and leaving a review on your preferred podcast platform. Your support helps us reach more people with important conversations like this one. Share this episode with someone who might benefit from hearing it—emotional eating is more common than we think, and this conversation could make a difference in someone's life.See omnystudio.com/listener for privacy information.
Approximately 75 million people with diabetes need to inject themselves daily with insulin. Research led by Dr Nick Hunt of the University of Sydney has developed a new type of oral insulin tablet based on nanotechnology.
Host Ben Owden engages in a thought-provoking conversation with Dr. Soumya Swaminathan, a renowned pediatric leader and former WHO Chief Scientist. They explore the interconnected relationship between health and climate change and the role of transformative leadership in addressing these complex challenges.The conversation explores the need for innovative thinking, diversity of thought, and collaboration to tackle these issues. Dr. Swaminathan shares insights from her career, stressing the importance of humility, empathy, and listening to affected communities in transformative leadership. She also addresses the challenges of misinformation and the necessity of public health communication.Ben Owden speaks with Dr. Muthoni Ntonjira, Managing Director and Health Systems District Leader for Philips East Africa. They explore the transformative impact of AI on healthcare, emphasizing the need for inclusivity and equity. Dr. Ntonjira shares her journey from a medical officer to a leader in health tech, highlighting the importance of diverse data sets in AI development and the critical role of women in decision-making positions. She discusses overcoming imposter syndrome, the significance of mentorship, and the necessity of male allyship to foster a supportive environment for women in tech. Important Links*Join Thrive in the Middle Today! *Book WhyLead to Train Your Teams*Explore Our ServicesSocial Media*Ben Owden's LinkedIn*Ben Owden's Twitter
Get Noticed! Send a text.Are you an entrepreneur struggling to scale your business efficiently? Discover how virtual assistants (VAs) can be your strategic partners, not just low-cost task handlers. Elizabeth Eiss, founder of Results Resourcing, reveals the power of hiring professional VA teams to boost your productivity and revenue. Learn why AI won't replace human VAs and how to leverage their expertise to optimise your business processes. Elizabeth shares insights on selecting the right VA, managing workflows effectively, and the true cost of DIY entrepreneurship. She introduces a fascinating ROI of Time Calculator to help you value your time and make informed decisions about outsourcing. Whether you're a solopreneur or small business owner, this episode offers valuable strategies to free up your time, focus on core activities, and accelerate business growth.Recommended book: "Thank You for Being Late: An Optimist's Guide to the Age of Acceleration" by Thomas L. FriedmanBuzzsprout - Let's get your podcast launched!Start for FREEBrilliant copy writing toolAI copywriting tool to generate unique copy, predict performance and increase conversions.Prowly - the media relations platformProwly has everything you need to get your PR work done.Build responsive quizzes.Generate higher quality, higher converting leadsDisclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the Show.Am I adding value to you?If so - I'd like to ask you to support the show.In return, I will continue to bring massive value with two weekly shows, up to 3 hours per month of brilliant conversations and insights.Monthly subscriptions start at $3 per month. At $1 per hour, that's much less than the minimum wage, but we'll take what we can at this stage of the business.Of course, this is still free, but as an entrepreneur, the actual test of anything is if people are willing to pay for it.If I'm adding value to you, please support me by clicking the link now. Go ahead, make my day :)Support the show here.
Lean Made Simple: Transform Your Business & Life One Step At A Time!
Welcome to Lean Made Simple, a podcast about transforming your business — and life — one step at a time. In this episode, Ryan Tierney from Seating Matters delves into standard work and how he is in the process of revolutionising his factory by documenting every single process. Along the way, he and Producer Matt talk about:- What is standard work?- The key piece of advice given to him by world class lean leaders. - What Toyota said about the standard work in his factory. - How to take your first step in creating standards- The simple tool Ryan and his team use to create standard works. Check it out! Links: - Book a Lean Made Simple Tour: https://www.leanmadesimple.com/book-a... - Send a voice message/question to the show: https://www.speakpipe.com/LeanMadeSimple- - GEMBADOCS: https://gembadocs.com/signup
In this episode of the IEA Podcast, Tom Clougherty and Matthew Lesh are joined by Sam Dumitriu, Head of Policy at Britain Remade, to discuss Labour's ambitious plans for housing, infrastructure, and economic growth. The conversation delves into the party's strategy to reform the planning system, restore housing targets, and streamline infrastructure projects. Sam provides insights into the challenges faced by previous governments and explores whether Labour's approach can overcome the long-standing obstacles to development in the UK. The discussion covers a range of topics, including the impact of NIMBYism, the complexities of the planning process, and the potential for private sector involvement in infrastructure projects. The panel examines the role of judicial reviews in delaying major developments and debates the merits of Labour's proposed National Wealth Fund. This episode offers a comprehensive analysis of the UK's housing and infrastructure challenges, providing listeners with a deeper understanding of the issues at stake and the potential solutions on the horizon. Our goal is to bring you a public affairs podcast with a difference. We want to get beyond the headlines and the shallow political commentary you'll get elsewhere and focus instead on the big ideas and foundational principles that classical liberals should care about. Get full access to Insider at insider.iea.org.uk/subscribe
Willow's Witty Wisdom: Revolutionising Houseplant Care. Cat Comforts: The PaWz Automatic Smart Litter Box Revolution. Travel Troubles: Tech-Driven Scams Skyrocket. Morse Mastery: Modern Magic with a Minimalist Morse Code Translator. Neurotargeting's Nefarious Nexus: Data-Driven Democracy Dilemma. Robotic Repetition: Humanoids Hone Skills by Shadowing Humans. Perth Pupils' Prolonged IT Prowess: Years of Hacking Exposed. Digital Discoveries: Delving into Genealogy with Gadgets. Emotional Empathy: Elevating AI's Understanding.
There's no such thing as totally 'straight', new study on sexuality says. NAKED FURY Female tourist sparks anger in Thailand after stripping naked and rubbing herself against sacred penis-shaped rock. Sex robots REVOLUTIONISE adult industry with cyborg babes starring in X-rated movies
© 2020-2025 Ivy Podcast Discovery LLC
